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Ovarian cancer is the seventh most common cancer in women and the most lethal 
gynecological cancer, causing over 151,000 deaths worldwide each year. Dysregulated 
production of endocrine hormones, known to have pluripotent effects on cell function 
through the activation of receptor signaling pathways, is believed to be a high-risk 
factor for ovarian cancer. An increasing body of evidence suggests that endocrine 
G protein-coupled receptors (GPCRs) are involved in the progression and metastasis 
of ovarian neoplasms. GPCRs are attractive drug targets because their activities are 
regulated by more than 25% of all drugs approved by the Food and Drug Administration. 
Therefore, understanding the role of endocrine GPCRs during ovarian cancer progres-
sion and metastasis will allow for the development of novel strategies to design effective 
chemotherapeutic drugs against malignant ovarian tumors. In this review, we address 
the signaling pathways and functional roles of several key endocrine GPCRs that are 
related to the cause, progression, and metastasis of ovarian cancer.
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G PROTeiN-COUPLeD ReCePTORS (GPCRs) AND  
OvARiAN CANCeR
According to the 2012 global cancer statistical report from the World Health Organization (WHO) 
BLOBOCAN project, approximately 200,000 new cases of ovarian cancer are reported annually 
(1–3). It is the second most common gynecological cancer and is associated with the higher mortal-
ity rate of any gynecological cancer. The high mortality rate is due to the aggressive but asympto-
matic progression of cancer cells throughout the peritoneal cavity, with more than 70% of patients 
being diagnosed at an advanced/metastatic stage (stage III or IV) (4). Because ovarian cancers are 
frequently diagnosed late, most patients present with extensive intraperitoneal tumors. Surgical 
debulking followed by chemotherapy is the mainstay of treatment for ovarian cancer, but it has not 
proven to be effective. The 5-year survival rate of patients undergoing salvage therapies is less than 
25%. More than 70% of patients are initially sensitive to platinum- and taxane-based chemotherapy, 
but recurrence and peritoneal metastases are found in more than half of these patients, leading to 
low overall survival rates (5). The WHO classifies ovarian cancer into epithelial, sex cord-stromal, 
and germ cell neoplasms. More than 90% of ovarian cancers arise from epithelial cells (6).
Fertility drugs, androgens, and other hormones used in replacement therapies are widely recog-
nized as risk factors for gynecological cancers (7, 8). Therefore, it has been proposed that endocrine 
hormones are critical to the development of malignant gynecological neoplasms. Hormone receptors 
are classified into three superfamilies: GPCRs, cytokine receptors, and nuclear receptors. Generally, 
water-soluble hormones bind GPCRs and cytokine receptors located on the cell membrane surface, 
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triggering a cascade of signaling events. Lipid-soluble hormones 
enter the cell and bind to nuclear receptors that can directly 
regulate gene transcription. The role of the nuclear and cytokine 
receptor families in ovarian cancer has been well established. For 
example, estrogen has been implicated in the progression of ovar-
ian cancer, where estrogen transduces pro-metastatic pathways 
via the nuclear estrogen receptor (ER). Recent epidemiological 
studies have demonstrated an elevation of ovarian cancer inci-
dence with the postmenopausal use of estrogen (7, 9).
G protein-coupled receptors are involved in many aspects 
of tumorigenesis, including the promotion of aberrant growth, 
increased cell viability, angiogenesis, and metastasis (10). Recent 
large-scale genomic analyses have discovered an abundance of 
mutations in G proteins and GPCRs (11). For instance, 20% of all 
sequenced human tumors contain mutations in GPCRs, includ ing 
mutations in the thyroid-stimulating hormone receptor (TSHR) 
(12), the luteinizing hormone receptor (LHR), and the follicle-
stimulating hormone receptor (FSHR), known to be involved 
in thyroid, breast, lung, and colon cancers, respectively (13). In 
another study, a mutant allele of GPRC5A was found to affect 
breast cancer risk (14), as lower levels of GPRC5A had adverse 
effect on the expression and function of BRCA1. Alterations 
in gene expression and promoter methylation of GPCRs in 
tumors have also been reported (10), and these changes appear 
to promote cancer proliferation, immune evasion, invasion of 
surrounding tissues, and increased resistance to hostile environ-
ments, such as hypoxia (15). In a study describing glioblastoma 
GPCR transcriptomes, 138 GPCRs were found to be aberrantly 
expressed, including several orphan receptors, such as GPR19, 
GPR82, GPR171, and GPR128 (16). Moreover, the orphan recep-
tor GPR161 was shown to be overexpressed in triple-negative 
breast cancer and correlated with poor prognosis (17). In the 
same study, GPR161 was found to be a major regulator of cell 
proliferation and migration through induction of rapamycin 
signaling.
Here, we will review the role of endocrine GPCRs in ovarian 
cancer. The term “endocrine GPCRs” refers to a subgroup of 
GPCRs with endogenous ligands (i.e., it excludes the G-protein-
coupled olfactory receptor). This review will focus on the 
following: (1) reproductive hormone receptors, including the 
G protein-coupled estrogen receptor (GPER), FSHR, and LHR; 
(2) hormone receptors that are involved in gonadotropin release, 
including the kisspeptin receptor (Kiss1R) and gonadotropin-
releasing hormone receptor (GnRHR); (3) other hormone 
receptors including endothelin receptors (ETRs) and angiotensin 
II type 1 receptor (AGTR1). The signaling network in different 
receptors is also described, and perspectives on the future of 
GPCR research in ovarian cancer research are given.
G PROTeiN-COUPLeD eSTROGeN 
ReCePTOR
Estrogens are sex hormones involved in regulating cell growth 
and differentiation in mammalian ovaries. A large-scale prospec-
tive cohort study conducted in the United States showed a strong 
link between ovarian cancer and estrogen. An increase in the 
risk of ovarian cancer was found in patients who had undergone 
estrogen replacement therapy (ERT), with the rate ratio (RR) 
rising to 1.23 [95% confidence interval (CI), 1.06–1.43]. For 
patients who had undergone ERT for more than 10 years, the RR 
increased to 2.2 (95% CI, 1.53–3.17) (7). This prospective study 
provided strong evidence that estrogen is a high-risk factor in 
postmenopausal women. However, a meta-analysis of 15 case 
studies did not find any correlation between ERT and ovarian 
cancer. The apparent contrast in results between each study may 
be due to the different genetic backgrounds of the patients tested 
or the sample sizes of each study. It is worth noting that ERT 
consists of treatment with both estrogen and another sex hor-
mone, progesterone. These two hormones have opposing effects 
on ovarian epithelial cells. Therefore, the effects of estrogen and 
progesterone should be considered and investigated separately.
Estrogens bind to two different types of receptors in mam-
malian cells. Two well-known ERs, ERα and ERβ, are nuclear 
receptors that affect gene expression by binding to estrogen 
responsive elements in the promoter region of target genes. 
Another is GPER (also known as GPR30), which belongs to 
the GPCR family of receptors, and mediates the non-genomic 
signaling of estrogens. GPER is expressed in various cancer cell 
lines and primary tumors of the breast, endometrium, ovaries, 
thyroid, lung, prostate, testicular germ cells, and brain (18). 
Even though GPER is widely expressed in tumors, its role in 
ovarian cancer is controversial. An early report proposed that 
elevated expression levels of GPER correlate with poor progno-
sis (19). Activation of GPER in ER-negative cells has also been 
shown to promote cell migration and invasion (20). However, 
contradictory results suggesting that high GPER expression is 
associated with a favorable prognosis have also been published 
(21, 22). In fact, the GPER selective agonist, G-1, significantly 
inhibited the proliferation of ovarian cancer cells by suppressing 
tubulin polymerization and arresting cell cycle progression (2, 
23). These conflicting results indicate that the role of GPER in 
ovarian cancer may vary from case to case. Several recent studies 
have suggested that cross talk between GPCRs might clarify the 
role of GPER during tumorigenesis. For example, the ability of 
GPER to serve as a prognosticator of cancer prognosis depends 
on gonadotropin receptor status. Increased expression of GPER 
predicted a longer survival period in patients negative for 
either FSHR or LHR compared to patients who were positive 
for FSHR and LHR. In addition, patients who tested nega tive 
for both FSHR and LHR had a more favorable prognosis than 
single-receptor negative patients (21). This observation suggests 
a mutually exclusive effect of GPER in association with LHR and 
FSHR during ovarian cancer progression.
With regards to the mechanistic activity of GPER, it appears 
that a signal transduction occurs primarily through the extracel-
lular signal-regulated and mitogen-activated protein kinase 
pathway. It has been shown that activation of GPER by estradiol 
induces ERK1/2 phosphorylation and promotes ovarian cancer 
proliferation regardless of ER status (24). In addition, GPER 
also activates cAMP and PIP2 signaling, inducing expression of 
matrix metalloproteinase 2 (MMP2) and MMP9, which, in turn, 
promote cancer metastasis (25). In breast and thyroid cancer 
cells, as well as endometrial cells, GPER exerts its effects through 
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the transactivation of the epidermal growth factor receptor 
(EGFR). For example, GPER activates the ERK1/2 pathway via 
the transactivation of EGFR in breast cancer cell lines (26). In 
ovarian cancer cells, activation of GPER promotes cell survival 
via the transactivation of EGFR and cross talk with the PI3K/
AKT signaling pathway (27).
The expression level of GPER is tightly associated with cell 
survival in epithelial ovarian cancer cells; a higher expression of 
GPER is correlated with a lower survival rate. Long et al. found 
that GPER expression correlates with tumor size and stage, lymph 
metastasis, and MMP9 expression (20, 28). ER-negative cells pro-
vide a clear picture of the role of GPER in ovarian cancer cell 
proliferation. 17β-Estradiol is a strong agonist of GPER that can 
enhance S-phase promotion and cell migration in ER-negative 
ovarian cancer cells (19, 20). Selective activation of GPER by G-1 
can also activate EGFR, upregulate c-fos, cyclin D1, cyclin E, 
and cyclin A, and promote cell proliferation (23). These in vitro 
studies provide strong evidence that GPER promotes ovarian 
cancer cell proliferation. However, a clinical study involving 40 
ovarian cancer patients with higher GPER expression found no 
association between clinical stage, pathological stage, and survival 
time (29). Tissue specimens from 124 ovarian cancers, 35 benign 
tumors, and 35 low-malignant tumors revealed that GPER is 
downregulated in ovarian cancer and that elevated expression of 
GPER correlates with a longer survival time. Additionally, GPER 
overexpression can induce G2/M cell cycle arrest via cyclin B1 
and CDC2 (22). Therefore, the ultimate result of GPER activa-
tion varies when co-expressed with other hormone receptors. For 
example, the effect of GPER activation is not only regulated by 
FSHR and LHR but also ER. It is apparent then that the role of 
GPER during ovarian cancer progression is highly complex and 
requires further investigation.
GONADOTROPiN-ReLeASiNG HORMONe 
ReCePTOR
Two forms of GnRHR have been discovered in mammals: 
GnRHR1 and GnRHR2. GnRHR1 is predominantly expressed in 
the hypothalamus and the pituitary and regulates reproduction 
in response to gonadotropin-releasing hormone (30). GnRHR2 
is mainly expressed in the midbrain. GnRHR2 appears to be 
involved in the regulation of sexual behavior and food intake (30). 
However, human GnRHR2 acquires frame shift mutations result-
ing in the appearance of an early stop codon and the production 
of a truncated version of the protein. Therefore, in this review, we 
will primarily focus on GnRHR1, hereby referred to as GnRHR.
Upon activation by its ligand (GnRH), GnRHR stimulates 
the synthesis and release of the gonadotropic hormones, FSH 
and LH. Because GnRHR is expressed in the ovary (31, 32), it is 
widely believed to be involved in ovarian cancer development and 
metastasis. The potential role of GnRHR as a tumor suppressor 
in ovarian cancer has been hypothesized because ovarian cancer 
patients with lower tumor expression levels of GnRHR showed 
more favorable survival rates (31). In vitro experiments also 
support this relationship as treatment with a specific GnRHR 
agonist (Buserelin) inhibited phosphatidylinositol kinase and 
exhibited a strong anti-mitogenic effect on ovarian carcinoma 
cells (33). In another study, the GnRHR agonist, [d-Ala6] GnRH, 
directly inhibited the growth of ovarian cancer cells in a time- and 
dose-dependent manner, whereas a GnRHR antagonist (Antide) 
reversed this effect (34).
Estradiol (E2) downregulated the expression of GnRHR and 
reduced GnRHR-mediated inhibition of proliferation in the ovar-
ian cancer cell line, OVCAR-3. However, in human ovary surface 
epithelial (hOSE) cells, estradiol did not affect the expression of 
GnRHR, and thus GnRH did not affect cell proliferation (35). 
These results indicate that GnRHR expression in ovarian cancer 
can be suppressed by the estrogen signaling pathway. Another 
study found that estrogen repressed GnRHR-mediated inhibition 
of proliferation in an ERα dependent manner via the upregula-
tion of c-Jun and the recruitment of the cAMP response element 
binding (CREB) protein (36). These results provide evidence that 
estradiol promotes the proliferation of ovarian cancer cells and 
overrides the antineoplastic effects of GnRHR. Because the role 
of GPER in OVACR-3 and hOSE cell proliferation and migration 
is unclear, further studies are required to explore the potential 
cross talk between GnRHR and GPER in regulating ovarian 
cancer progression.
The signaling pathways regulated by GnRHR appear to be 
tissue specific. Classic GnRHR signaling in pituitary gonado-
trophs is responsible for the activation of protein kinase 
C (PKC), phospholipase C (PLC), and adenylyl cyclase. Upon 
ligand bind ing, GnRHR activates phosphotyrosine phosphatase 
(PTP), which inactivates the epidermal growth factor receptor/
mitogen-activated protein kinase signaling pathway via dephos-
phorylation of the EGFR. GnRHR inhibits proliferation through 
the activation of PKC, which is followed by phosphorylation and 
activation of ERK1/2. Interestingly, this antiproliferative effect 
can be reversed by blocking GnRHR, which has been shown 
to play a critical role in this process. With respect to GnRHR2, 
it has been reported that this receptor is non-functional (37). 
However, the role of GnRHR2 in ovarian cancer requires 
fur ther investigation. One study showed that treatment with 
GnRH-I or GnRH-II inhibits PTP and subsequently inactivates 
MAPK signaling. More specifically, analogs of GnRH-I and 
GnRH-II reduced EGF-triggered mitogenic signal transduc-
tion (38). Transcriptomic and proteomic approaches were used 
to investigate the effects of triptorelin, an agonist of GnRHR, 
on ovarian cancer cells. Triptorelin has been shown to be an 
effective promoter of cell cycle arrest by inhibiting G2/M phase 
progression, eventually leading to apoptosis. This effect appears 
to be mediated by NF-κB phosphorylation and AKT inactiva-
tion (39).
In contrast to the studies listed above, it has been shown that 
GnRHR antagonists exhibit antiproliferative properties in ovarian 
cancer cells by inducing cell apoptosis via the activation of p38 
and c-Jun mediated Bax expression. Increased Bax expression 
ultimately leads to mitochondrial dysfunction and subsequent 
activation of the intrinsic pathway of apoptosis (40). Intriguingly, 
GnRHR antagonists appear to be less cytotoxic and more potent 
in mouse models of cervical cancer compared to GnRHR agonists 
(41). The uniformity of the GnRH-II agonist and antagonist on 
cancer cell proliferation probably result from cell stress caused 
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by hyperactive or over deterrence related signaling. Cross talk 
between EGF and GnRH-II signaling also appears to promote 
ovarian cancer metastasis. Specifically, EGF induces the expres-
sion of GnRH-II by promoting CREB-dependent transcription, 
resulting in ovarian cancer invasion (42). Other studies have 
shown that GnRH-II can enhance cancer cell adhesion, thereby 
promoting migration and invasion, by increasing laminin recep-
tor expression levels (43).
In conclusion, GnRHR is a critical regulator of ovarian cancer 
cell proliferation. Both hyperactivity (i.e., high doses of GnRH, 
~100  nM) and inhibition of GnRHR can suppress cancer cell 
proliferation and induce apoptosis. However, lower doses of 
GnRH-II (~10 nM) can promote cancer cell invasion and migra-
tion. Therefore, imbalances in the levels of GnRHR activity appear 
to modulate the rate of cancer cell proliferation and metastasis.
FOLLiCLe-STiMULATiNG HORMONe 
ReCePTOR
All ovarian epithelial tumors express FSHR, and the expression 
level of FSHR is positively correlated with tumor grade (44). FSH 
is known to stimulate ovarian cancer cell proliferation, and this 
effect can be reversed by exposure to LH. These observations may 
explain why FSH treatment does not increase ovarian cancer risk 
in postmenopausal women (45). LHR and FSHR are generally 
co-expressed in the ovaries of postmenopausal women, and the 
co-regulation of LHR and FSHR signaling is essential to maintain 
normal function of the ovaries. Investigation into the underlying 
molecular pathogenesis of ovarian cancer has provided evidence 
that FSHR activation can influence cancer related gene expression. 
For example, FSH can downregulate tumor suppressor genes, 
including RB1 and BRCA1 (46), and overexpression of FSHR 
increased protein levels of Her2, c-myc, EGFR, and ERK1/2 (47), 
resulting in ovarian cancer cell proliferation. In addition, FSH 
was found to regulate ovarian cancer mitosis via the PI3K/AKT/
HIF-1/cyclin-D1 signaling pathway (48). It appears that FSHR 
not only enhances cell growth but also promotes the invasiveness 
of ovarian cancer cells. Furthermore, it has been shown that acti-
vation of FSHR triggers the PI3K/AKT/Snail signaling pathway, 
activates ERK1/2, and upregulates expression of OCT4, thereby 
promoting cancer cell epithelial–mesenchymal transition, migra-
tion, and distant invasion (49, 50).
Several groups have already begun testing FSHR inhibitors for 
their ability to inhibit the progression of ovarian cancer. In one 
study, an FSH analog complexed with either paclitaxel or cisplatin 
inside nanoparticles enhanced the potency and selectivity of 
the chemotherapeutic drug to target ovarian cancer cells, while 
showing a reduction of unwanted side effects. Here, the selectiv-
ity of these complexed nanoparticles for ovarian cancer cells was 
enhanced using an FSH peptide conjugated to poly-amidoamine 
dendrimers. These particles have been previously shown to per-
form better than non-targeted administration with regards to 
inhibition of ovarian cancer proliferation and lymphatic metas-
tasis (51, 52). Moreover, FSHR-based targeting has shown to have 
potent anticancer effects in both in vitro and in vivo models (53). 
In another study, anti-FSHR immune receptors were used to 
redirect T cells to ovarian tumors by inducing the expression of 
anti-FSHR immune receptors in the patient’s T lymphocytes. The 
anti-FSHR immune receptor then triggered T-mediated cytotox-
icity in ovarian cancer cells (54). This promising approach could 
potentially recruit T lymphocytes to ovarian cancer tumors and 
not only initiate T cytotoxicity and continuous tumor immune 
responses but also reduce adverse side effects by limiting cytotox-
icity to the site of the tumor.
LUTeiNiZiNG HORMONe ReCePTOR
Previous studies have shown LHR to be expressed abundantly in 
the plasma membrane of ovarian epithelial cells (55). Moreover, 
low-grade ovarian cancer tumors express LHR to a higher degree 
than high-grade tumors, which suggests that LHR may play a 
role in ovarian cancer progression. LH is known to regulate the 
expression of several genes related to cell growth and apoptosis. 
It is worth noting that LH generally upregulates genes related to 
proliferation. Studies have shown that LH induces the expression 
of ERBB receptor tyrosine kinase 2 (ERBB2), which promotes cell 
proliferation. However, upregulation of ERBB2 alone was insuf-
ficient to enhance cell proliferation and survival of ovarian cancer 
cells (56). Interestingly, it was also found that activation of the 
LHR reduces cell invasion and proliferation. Studies have shown 
that MMP family members, such as MMP2 and MMP9, are 
downregulated by LHR activation, while cell adhesion and base-
ment membrane proteins (COL4A3, COL4A4, NID2, ITGB8, 
and LAMA3) were upregulated (56). These results might explain 
why treatment with LH suppresses ovarian cancer invasion. By 
screening using an miRNA-specific array, several antiprolifera-
tion miRNAs, including miR-101, miR-301, and miR-210, were 
found to be upregulated by LH treatment (57). Furthermore, LH 
appears to activate the PTP pathway via Ga(i) and counteracts 
mitogenic signal transduction induced by EGF (58), suggesting 
that the interaction of LHR and EGFR is essential for determining 
the fate of ovarian cancer cells.
Because LHR localizes to the cell surface of ovarian cancer 
cells, several studies have used LHR as a cancer biomarker for 
targeted therapy and have obtained moderately positive results. 
For example, using a nanoparticle that links CD44-siRNA to an 
LH analog in combination with paclitaxel significantly enhanced 
cell death in ovarian tumors (59). However, as LHR expression is 
generally decreased during tumorigenesis, this treatment would 
not be suitable for advanced stages of ovarian cancer.
THYROiD-STiMULATiNG HORMONe 
ReCePTOR
Because TSHR is mainly found in the thyroid, scientists have 
primarily focused on the role of TSHR in thyroid cancer pro-
gression. However, recent evidence suggests that TSHR is highly 
expressed in ovarian cancer tumors (60). Patients with high 
tumor TSHR expression levels had lower survival rates compared 
to patients with low TSHR tumor expression levels (61). There 
remain discrepancies about the role of TSHR in thyroid and 
ovarian cancers: (1) TSHR was found to be downregulated in 
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thyroid cancer but highly expressed in ovarian cancer and (2) 
high TSHR expression was found to predict increased survival 
rates for thyroid cancer patients but poorer outcomes for patients 
with ovarian cancer (62). Therefore, TSHR activity appears to 
be correlated to ovarian cancer progression. However, further 
investigation is required to discern the role of TSHR in ovarian 
tumorigenesis.
KiSSPePTiN ReCePTOR
Kisspeptin receptor has been identified as a tumor suppressor 
in breast cancer and melanoma (63, 64). However, recent evi-
dence suggests that kisspeptin (Kiss1) and Kiss1R are involved 
in ovarian cancer progression. Despite the similarity of Kiss1R 
expressions levels between malignant and benign ovarian 
tumors, the expression of Kiss1 was found to be significantly 
higher in malignant ovarian tumors. More importantly, Kiss1 
expression levels negatively correlated with the clinical stage 
diagnosis (65). Immunohistochemical analysis of 518 ovarian 
cancer tumor samples suggested a favorable prognostic role 
of Kiss1R with regards to the total survival duration as well 
as the disease-free survival period. Therefore, it appears that 
the activation of Kiss1/Kiss1R indicates a favorable prognosis. 
Patient plasma kisspeptin levels also correlated with cancer 
metastasis, and levels of kisspeptin lower than 20 pmol/L have 
been associated with a higher risk of ovarian cancer metastasis 
(66). Additionally, high expression levels of Kiss1R decreased 
the lysophosphatidic acid induced migration of ovarian cancer 
cells. In another study, kisspeptin treatment inhibited cancer 
cell migration in a PKC-dependent manner (67), and decreased 
stromal cell-derived factor 1 (SDF-1) mediated tumor migra-
tion by suppressing AKT phosphorylation (63). Kisspeptin-10 
can also activate Kiss1R and influence the binding efficiency of 
SDF-1/CXCL12 with its cell surface receptor, CXCR4, thereby 
inhibiting metastasis. Altogether, these results are indicative of 
the tumor suppressing nature of Kiss1 and its receptor, Kiss1R, 
in ovarian cancer.
ANGiOTeNSiN ii TYPe 1 ReCePTOR
Angiotensin II type 1 receptor is a key member of the renin–
angiotensin system. This receptor is mainly expressed in the 
liver, lungs, kidneys, and adrenal glands. Recently, a study 
demonstrated, by immunohistohemical staining, that ovarian 
tumors express AGTR1. Survival analysis (from The Cancer 
Genome Atlas database) found that the expression level of 
AGTR1 is directly related to the overall survival and disease-
free survival rate and that high AGTR1 expression indicates an 
unfavorable prognosis. Pathologic analysis showed that elevated 
expression of AGTR1 correlated with high microvessel density 
and an increased secretion of vascular endothelial growth factor 
(VEGF) (68). Serum levels of angiotensin II converting enzyme 
(ACE), the key enzyme responsible for production of angioten-
sin II, were shown to be significantly increased in ovarian cancer 
patients. However, no correlation was found between angioten-
sin II and Ca-125, a glycoprotein biomarker of advanced ovarian 
cancer. These results suggest that changes in the expression levels 
of ACE are an early event during carcinogenesis and could be 
used as an efficient biomarker for the diagnosis of ovarian 
cancer compared to angiotensin II or Ca-125. Because ovarian 
cancer cells invade surrounding tissues through the peritoneal 
cavity, understanding the role of angiotensin II and ACE dur-
ing metastasis will be essential to assess how AGTR1 regulates 
cancer progression. Future studies will determine the correlation 
between serum and peritoneal fluid angiotensin II levels and 
ovarian tumorigenesis.
BRCA1, one of the most well-studied tumor suppressor genes, 
is responsible for DNA repair post injury. Studies have shown 
that there is a positive correlation between BRCA1 and AGTR1 
levels in ovarian tumors. Wild-type BRCA1 patients show 
higher tumor expression levels of AGTR1 compared to patients 
with BRCA1 mutations. Elevated expression of BRCA1 has 
been shown to significantly promote the expression of AGTR1. 
However, knockdown of BRCA1 did not affect AGTR1 expres-
sion. The positive regulation of AGTR1 by BRCA1 implies that 
AGTR1 might maintain the integrity of the cell’s genome and 
reduce apoptotic signaling throughout carcinogenesis, without 
promoting cell mitosis (69). Other studies have demonstrated 
that angiotensin II can increase endothelial nitric oxide (eNOS) 
and upregulate cyclooxygenase-2, thereby enhancing angiogen-
esis (70). In mesenchymal stem cells, AGTR1 induced HIF-1a 
expression and resulted in the upregulation of VEGF and ACE. 
In general, VEGF stimulates endothelial cell proliferation and 
migration, processes which contribute to tumor angiogenesis, 
while ACE accelerates the de novo production of angiotensin II, 
which forms a positive feedback loop (71). Therefore, AGTR1 
antagonists might be useful for suppressing tumor angiogenesis 
in ovarian cancer. Targeting AGTR1 could significantly inhibit 
tumor growth via inactivation of the phosphorylation of PLC 
β3, which could disrupt tumor angiogenesis by reducing the 
VEGF production, thus inhibiting endothelial cell survival (72). 
However, the source of the VEGF secretion (either endothelial 
cells or ovarian cancer cells) and the molecular mechanism 
responsible for angiotensin II-mediated endothelial cell 
migration and microvessel formation remain unknown. Thus, 
elucidating the role of AGTR1 during ovarian cancer metastasis 
will prove integral to developing AGTR1-targeted drugs for the 
treatment of ovarian cancer.
eNDOTHeLiN ReCePTOR
There exist two types of ETRs: the endothelin A receptor (ETAR) 
and the endothelin B receptor (ETBR). All metastatic ovarian 
cancers and 90% of primary ovarian cancers express ETAR, 
whereas around 40% of ovarian tumors express ETBR. The 
ovarian cancer cell lines, PEO4 and PEO14, not only express 
ET-1 (endothelin 1) and ET-3 (endothelin 3) but also ETAR 
and ETBR, which suggests that ovarian cancer cells stimulate the 
ETR pathway in an autocrine fashion. ETAR agonists have been 
shown to exhibit strong antitumor activities compared to ETBR 
agonists, indicating that ETAR plays a more significant role 
during cancer progression in response to endothelin exposure 
compared to ETBR (73). One study found that endothelin could 
induce VEGF production via the HIF-1a pathway, resulting 
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in neovascularization of ovarian tumors (74). Endothelin also 
induced cyclooxygenase 1/2 expression and increased expression 
levels of prostaglandin E2 and prostaglandin E4, resulting in 
VEGF production and promotion of angiogenesis. Furthermore, 
the activation of ETRs upregulated MMP-2, -3, -7, -9, and -13, 
critical mediators of cellular invasion. Integrin-linked kinase 
(ILK) also appears to be involved in transducing extracellular 
endothelin signals, mediating the activation of PI3K/AKT and 
promoting cell motility and invasion (74). It was also found that 
β-arrestin acts as an ETAR signal transducer by inactivating 
GSK-3β through the PI3K/ILK/AKT pathway, thereby promot-
ing WNT signaling and contributing to the chemoresistance, 
invasion, and metastasis of ovarian tumors.
Drug resistance is a major challenge in the treatment of ovarian 
cancer with paclitaxel therapy. Because endothelial cells generally 
enhance ovarian cancer cell survival, previous attempts to target 
ovarian tumors included the use of an ETR agonist (Atrasentan, 
ABT-627) to inhibit cell proliferation and VEGF production and 
to reduce ILK expression and phosphorylation of GSK-3β (75). 
Ovarian tumors are known to become resistant to paclitaxel. 
However, administration of ABT-627 in combination with 
paclitaxel yielded improved results with regards to the inhibition 
of angiogenesis and the induction of apoptosis. In a separate 
study, the endothelial receptor antagonist, ZD4054, reduced 
cancer cell survival, invasion and angiogenesis and enhanced 
the chemotherapeutic sensitivity of ovarian tumors. ZD4054 
effectively induced apoptosis by inhibiting Bcl-2 and activating 
caspase 3 (76). Furthermore, it was found that gene silencing of 
the endothelial converting enzyme resulted in the suppression of 
endothelial mediated cell proliferation and invasion via inhibition 
of MAPK phosphorylation, which suppressed MMP2 activity and 
upregulated the ratio of E-cadherin to N-cadherin (77). Finally, 
epigallocatechin-3-gallate, a polyphenol derived from green tea 
considered to be a potent natural anticancer small molecule, has 
been shown to reduce ovarian cancer progression by targeting 
ETAR, making it a potentially cost effective method of preventing 
ovarian cancer.
THe ReCePTOR NeTwORK iN OvARiAN 
CANCeR
The physiology of the ovary is precisely regulated by the repro-
ductive hormones and receptors of the HPG axis. These receptor 
signaling cascades are not only found in the ovary but also in 
ovarian tumors. Evidence suggests that ovarian cancer develop-
ment is tightly associated with dysregulated hormonal signaling. 
More importantly, hormone receptor expression patterns and the 
modulation of intricate signaling networks appear to determine 
the fate of cancer cells. The role of GPCRs in regulating ovarian 
cancer development is summarized in Table  1. In our model, 
Kiss1R, GnRHR, and LHR act as cancer suppressors by inhibiting 
proliferation and metastasis. FSHR acts as an oncogene in ovarian 
cancer by promoting cell proliferation and survival and antago-
nizes the tumor suppressing effects of LHR. GPCRs involved 
in cardiovascular function, such as AGTR1 and ETR, can also 
modulate the progression of ovarian cancer. Activation of AGTR1 
and ETR has been shown to enhance angiogenesis and promote 
metastasis. While the effects of AGTR1 and ETR activity during 
tumorigenesis have been well studied, the relationship between 
these receptors and classic reproductive hormone GPCRs requi-
res further investigation. In conclusion, numerous GPCRs and 
their specific ligands are likely important in ovarian cancer 
development and metastasis. Therefore, fully characterizing the 
roles of these GPCRs during tumorigenesis will greatly benefit 
the development of novel chemotherapeutics.
AUTHOR CONTRiBUTiONS
All authors have made substantial, direct, and intellectual contri-
bution to the work and approved it for publication.
FUNDiNG
LL was supported by FDCT grant, Macao (FDCT101/2015/A3) 
and MYRG2016-00075-FHS.
TABLe 1 | Summary of the role and pathways of G-protein-coupled receptors in ovarian cancer.
Receptor Ligand Function Pathway Reference
G-protein-coupled estrogen 
receptor
Estradiol Regulate metastasis, and proliferation PI3K/AKT/MMP-9 (24–27)
GnRHR1 GnRH-I, GnRH-II Antiproliferation P38/c-Jun/MAPK, Bax/caspase9 (37–39)
Follicle-stimulating hormone 
receptor
Follicle-stimulating 
hormone
Enhance proliferation, cell survival, 
metastasis
PI3K/AKT/HIF-1/cyclin-D1, ERK1/2MAPK (47–50)
Luteinizing hormone receptor Luteinizing hormone Inhibits metastasis, suppress proliferation cAMP/phosphotyrosine phosphatase/EGFR (56, 58)
Thyroid-stimulating hormone 
receptor
Thyrotropin Predicate good outcome Unknown (61, 62)
Angiotensin II type 1 receptor Angiotensin II Enhance angiogenesis eNOS/cyclooxygenase-2 (COX2)/HIF-1α/vascular 
endothelial growth factor (VEGF)
(68, 70, 71)
Kisspeptin receptor Kisspeptin Inhibits proliferation and migration Stromal cell-derived factor 1/CXCL12/CXCR4/AKT (63, 67)
Endothelin receptor Endothelin Enhance angiogenesis and metastasis PI3K/integrin-linked kinase/AKT, COX2/PE/ 
HIF-1α/VEGF
(74–77)
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